The Biotech Diversity Gap Is Real. Here’s How One Nonprofit Incubator Is Closing It.

by DAVID.KIEWLICH | Aug 13, 2026 | Biotech

Biotech is the cutting edge of human advancement. Gene therapies are curing rare diseases. Cell-based immunotherapies are redefining oncology. Carbon-capturing biology and engineered materials are shaping climate change. The research has never been more exciting. Yet...

Succeed or Learn, There Is No Fail: The Radical Mindset Behind a 95% Biotech Success Rate

by DAVID.KIEWLICH | Aug 7, 2026 | Biotech

Nearly 90% of biotech startups fail. This number is so ingrained in biotech that almost everyone treats it as a given. But maybe we are looking at things backwards. What if failing wasn’t the opposite of success, but what you needed to get there? At BADASS Labs, our...

From Pipette to Pitch Deck: How Biotech Founders Raise Millions Without Giving Away the Store

by DAVID.KIEWLICH | Jul 31, 2026 | Biotech

You have the science. You have the vision. You may even have a handful of early results that make your blood boil at 3 a.m. And yet, as a biotech founder, the hardest task is probably the first one that gets you up in the morning: fundraising. Raising money for a...

The De-Risking Playbook: How BADASS Labs Helps Biotech Startups Build the Data VCs Demand in 2026

by DAVID.KIEWLICH | Jul 30, 2026 | Biotech

Let’s be blunt: biotech funding in 2026 is not about great science anymore. It is about proven science. Venture capitalists are actively seeking out biotechs with existing data sets and de-risked pipelines; the days of backing a tantalizing hypothesis and a...

Cheap Cell Therapy Lab Space: Bringing Advanced Therapeutics to Any Budget

by DAVID.KIEWLICH | Jul 24, 2026 | Cell Therapy

The age of cell and gene therapy is here. The FDA has already approved more than 30 cell and gene therapies since 2017, and the global AAV manufacturing market is continuing to expand. Science, however, has outpaced the infrastructure. Before startups run into a...